Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2006 1
2007 4
2008 2
2009 7
2010 5
2011 2
2012 5
2013 2
2015 1
2016 1
2017 2
2018 4
2019 1
2020 1
2021 4
2022 4
2023 2
2024 3
2025 3
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Results by year

Filters applied: . Clear all
Page 1
Testosterone use for hypoactive sexual desire disorder in postmenopausal women.
Parish SJ, Kling JM. Parish SJ, et al. Menopause. 2023 Jul 1;30(7):781-783. doi: 10.1097/GME.0000000000002190. Epub 2023 Jun 13. Menopause. 2023. PMID: 37314872
Testosterone is an important evidence-based therapy for hypoactive sexual desire disorder (HSDD) in postmenopausal women. ...This Practice Pearl will discuss evidence-based testosterone therapy for management of HSDD in p …
Testosterone is an important evidence-based therapy for hypoactive sexual desire disorder (HSDD) in postmenopausal …
Testosterone for the Treatment of Hypoactive Sexual Desire Disorder in Perimenopausal and Postmenopausal Women.
Kling JM. Kling JM. Obstet Gynecol. 2025 Jul 24;146(3):341-349. doi: 10.1097/AOG.0000000000006015. Obstet Gynecol. 2025. PMID: 40706034 Review.
Although there is no androgen deficiency diagnosis for women, research demonstrates that testosterone treatment can be modestly beneficial in treating appropriately selected postmenopausal women with distressing low desire, also known as hypoactive sex …
Although there is no androgen deficiency diagnosis for women, research demonstrates that testosterone treatment can be modestl …
The clinical management of testosterone replacement therapy in postmenopausal women with hypoactive sexual desire disorder: a review.
Uloko M, Rahman F, Puri LI, Rubin RS. Uloko M, et al. Int J Impot Res. 2022 Nov;34(7):635-641. doi: 10.1038/s41443-022-00613-0. Epub 2022 Oct 5. Int J Impot Res. 2022. PMID: 36198811 Free PMC article. Review.
There is gaining interest in the use of Testosterone Replacement Therapy (TRT) for the treatment of HSDD in postmenopausal women. ...Our results conclude that testosterone is a vital hormone in women in maintaining sexual health an …
There is gaining interest in the use of Testosterone Replacement Therapy (TRT) for the treatment of HSDD in postmeno …
International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women.
Parish SJ, Simon JA, Davis SR, Giraldi A, Goldstein I, Goldstein SW, Kim NN, Kingsberg SA, Morgentaler A, Nappi RE, Park K, Stuenkel CA, Traish AM, Vignozzi L. Parish SJ, et al. J Sex Med. 2021 May;18(5):849-867. doi: 10.1016/j.jsxm.2020.10.009. Epub 2021 Apr 1. J Sex Med. 2021. PMID: 33814355 Free article. Review.
BACKGROUND: The Global Consensus Position Statement on the Use of Testosterone Therapy for Women (Global Position Statement) recommended testosterone therapy for postmenopausal women with hypoactive sexual desire disorder (HSDD …
BACKGROUND: The Global Consensus Position Statement on the Use of Testosterone Therapy for Women (Global Position State …
Medical Treatment of Female Sexual Dysfunction.
Nappi RE, Tiranini L, Martini E, Bosoni D, Righi A, Cucinella L. Nappi RE, et al. Urol Clin North Am. 2022 May;49(2):299-307. doi: 10.1016/j.ucl.2022.02.001. Urol Clin North Am. 2022. PMID: 35428435 Review.
Flibanserin and bremelanotide are psychoactive agents indicated for the treatment of generalized acquired hypoactive sexual desire disorder (HSDD) in premenopausal women, whereas transdermal testosterone is effective on HSDD in postmenopausal …
Flibanserin and bremelanotide are psychoactive agents indicated for the treatment of generalized acquired hypoactive sexual desire disorder …
Androgen Therapy in Women.
Vegunta S, Kling JM, Kapoor E. Vegunta S, et al. J Womens Health (Larchmt). 2020 Jan;29(1):57-64. doi: 10.1089/jwh.2018.7494. Epub 2019 Nov 5. J Womens Health (Larchmt). 2020. PMID: 31687883 Review.
Testosterone, the primary ovarian androgen, has been used to treat carefully selected postmenopausal women with hypoactive sexual desire disorder (HSDD). ...A trial of low-dose testosterone therapy may be considered for carefully selected …
Testosterone, the primary ovarian androgen, has been used to treat carefully selected postmenopausal women with hypoact …
The safety of testosterone therapy in women.
Al-Imari L, Wolfman WL. Al-Imari L, et al. J Obstet Gynaecol Can. 2012 Sep;34(9):859-865. doi: 10.1016/S1701-2163(16)35385-3. J Obstet Gynaecol Can. 2012. PMID: 22971455 Review.
Although no androgen therapies for female sexual dysfunction are currently approved for use in Canada, clinical trials support the efficacy and short-term safety of testosterone therapy for HSDD. We review the scientific evidence for the safety of t …
Although no androgen therapies for female sexual dysfunction are currently approved for use in Canada, clinical trials support the ef …
Androgen therapy for women after menopause.
Marko KI, Simon JA. Marko KI, et al. Best Pract Res Clin Endocrinol Metab. 2021 Dec;35(6):101592. doi: 10.1016/j.beem.2021.101592. Epub 2021 Oct 12. Best Pract Res Clin Endocrinol Metab. 2021. PMID: 34674962 Review.
Androgens are essential hormones in women. Yet, androgen therapy is understudied and underutilized despite showing improvement in postmenopausal hypoactive sexual desire disorder (HSDD) and the genitourinary syndrome of menopause (GSM). ...Beyond HS …
Androgens are essential hormones in women. Yet, androgen therapy is understudied and underutilized despite showing improvement …
The role of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women.
Krapf JM, Simon JA. Krapf JM, et al. Maturitas. 2009 Jul 20;63(3):213-9. doi: 10.1016/j.maturitas.2009.04.008. Epub 2009 May 31. Maturitas. 2009. PMID: 19487090 Review.
Although early research established that testosterone therapy improves sexual desire in postmenopausal women, safer and more efficacious administration routes were explored. ...More recent studies are exploring the utility of testosterone gels. …
Although early research established that testosterone therapy improves sexual desire in postmenopausal women, sa …
Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis.
Achilli C, Pundir J, Ramanathan P, Sabatini L, Hamoda H, Panay N. Achilli C, et al. Fertil Steril. 2017 Feb;107(2):475-482.e15. doi: 10.1016/j.fertnstert.2016.10.028. Epub 2016 Dec 1. Fertil Steril. 2017. PMID: 27916205 Free article.
OBJECTIVE: To systematically review and summarize the existing evidence related to the efficacy and safety of transdermal T in postmenopausal women for the treatment of hypoactive sexual desire disorder (HSDD). DESIGN: Systematic reviews and meta-analysis. .. …
OBJECTIVE: To systematically review and summarize the existing evidence related to the efficacy and safety of transdermal T in postmenopa …
50 results